Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules

Ranjana H. Advani, Daniel C. Adelman, Michael S. Gordon et al.|Clinical Cancer Research|2010

Cited by 45